In silico analysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells

doi:10.3748/wjg.v31.i3.95207

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2080)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-3) series.

Item

Count

PDF

HTML

1260

Figures (1-7)

233

Tables (1-3)

223

Sum=1763

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

187

Sum=223

Jan 21, 2025 (publication date) through Apr 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jan 21, 2025; 31(3): 95207
Published online Jan 21, 2025. doi: 10.3748/wjg.v31.i3.95207

Full Size Figure Download Figure

Figure 3 Identification of mRNA candidates. A: Diagram representing the study design; B: Bubble plots of enriched GSEA terms in HepG2 cells; C: SNU449 cells treated with Sorafenib 24 hours. Bubble size is representative of gene count and color is representative of the normalized enrichment score; D: Heatmap of selected mRNAs in HepG2 and SNU449 cells.

Citation: de la Cruz-Ojeda P, Parras-Martínez E, Rey-Pérez R, Muntané J. In silico analysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells. World J Gastroenterol 2025; 31(3): 95207
URL: https://www.wjgnet.com/1007-9327/full/v31/i3/95207.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i3.95207